A Breakthrough in Wound Management: LifeNet Health Unveils Dermacell® Porous, Now Accessible Nationwide

VIRGINIA BEACH, Va., April 23, 2025 /PRNewswire/ -- More than 38 million Americans, roughly 1 in 10, are living with diabetes, with up to 95% affected by type 2 diabetes, a condition often linked to limited access to quality health care.¹ This issue is especially stark in underserved communities, where barriers to care contribute to the rising prevalence and devastating complications. LifeNet Health, a global leader in regenerative medicine, is breaking down these barriers through innovative solutions that empower healthcare providers, strengthen communities, and honor the gift of donation. Advancing its mission of saving lives, restoring health, and giving hope, LifeNet Health launches Dermacell Porous, its next-generation human acellular dermal matrix processed to retain endogenous growth factors, collagen, and elastin in a biohospitable scaffold.^5,6,11

Dermacell Porous is designed to help close chronic wounds in four or fewer applications, making it 1 of 26 skin substitute grafts and cellular or tissue-based products (CTPs) covered under Medicare's new Local Coverage Determinations (LCDs) now planned to go into effect January 1, 2026.^1,3 This innovative solution expands LifeNet Health's extensive portfolio of regenerative wound solutions, reinforcing its commitment to providing clinicians with advanced, accessible options for wound care.

Dermacell Porous stands out for its thin, durable, and naturally porous structure, enhanced by LifeNet Health's proprietary Matracell^® technology for superior performance.^2,12 Unlike other product alternatives, LifeNet Health's advanced technologies result in an extracellular matrix (ECM) that contains all the collagens, elastin, proteins, growth factors, matrikines, and cytokines present in the donor tissue.^5,6 The advanced processing and terminal sterilization technologies also render Dermacell Porous sterile with validated viral inactivation, providing healthcare professionals and their patients with the peace of mind they deserve.^4,8

Dr. Loan Lam, Medical Director of Wound Services at United Vein & Vascular Centers, was the first clinic to utilize Dermacell Porous and continues to be very impressed with the clinical outcomes. "With Dermacell Porous, not only does a thin intact dermal structure provide a good initial physical scaffold, but we see faster incorporation and better integration, and more predictable healing," said Dr Lam.

Clinical studies and randomized trials show a 135% higher healing rate and 148% greater wound reduction with Dermacell AWM/Porous compared to standard dressings.⁹ Additionally, a Dermacell AWM/Porous study on Wagner 3 and 4 wounds demonstrated an 84% lower amputation rate.¹⁰ Dermacell Porous is yet another way LifeNet Health continues to give healing every advantage.

Daniel Osborne, Chief Growth Officer at LifeNet Health, emphasized the company's broader mission, "At LifeNet Health, our goal is to transform patients' lives through innovation and compassionate care. The introduction of Dermacell Porous is testament to our commitment to addressing critical health care challenges and ensuring greater access to regenerative wound care solutions. This product reflects our dedication to honoring donors by delivering advancements that promote healing and empower both patients and health care providers."

Dermacell Porous offers key benefits for wound closure, including faster full incorporation with enhanced vascularization and cell infiltration, an intact dermal structure, and easy non-sided application.^{5-7, 11} It's ready to use straight from the package with room-temperature shelf stability, simplifying storage and logistics for healthcare professionals.⁷

About LifeNet Health
LifeNet Health is a global leader in regenerative medicine, providing a comprehensive range of transplant solutions from organ procurement to bio-implants and cellular therapies. LifeNet Health's mission is to improve the quality of human life by advancing medical possibilities in transplantation and research.

References:

1. Centers for Disease Control and Prevention. (n.d.). About type 2 diabetes. U.S. Department of Health & Human Services. https://www.cdc.gov/diabetes/about/about-type-2-diabetes.html
2. Cazzell, S., Vayser, D., Pham H., et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair and Regeneration. 2017.
3. Centers for Medicare & Medicaid Services. (2024). Local Coverage Determination (LCD): Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers (LCD ID: 39756, Version 7).
4. LifeNet Health, PQ-10-008, Process Qualification: Method 2B Terminal Sterilization Validation for the Devitalized Dermis Allografts Family
5. 68-20-047, Analysis of the Acellular Matrix, Growth Factors, and Cytokines Present in Oracell.
6. LifeNet Health, TR 0292, LifeNet Health's Decellularized Dermis, Dermacell, Comparison to the USP Monograph, Scaffold Human Dermis.
7. Moore MA, Samsell B, Wallis G, et al. Decellularization of human dermis using non-denaturing anionic detergent and endonuclease: a review. Cell Tissue Bank. 2015; 16(2):249-²259. https://doi.org/10.1007/s10561-014-9467-4
8. Moore MA. Inactivation of enveloped and non-enveloped viruses on seeded human tissues by gamma irradiation. Cell Tissue Bank. 2012 Aug;13(3):401-7. doi: 10.1007/s10561-011-9266-0.
9. Cazzell, S., Vayser, D., Pham H., et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair and Regeneration. 2017. 25(3):483-497.
10. Cazzell S, Moyer PM, Samsell B, Dorsch K, McLean J, Moore MA. A Prospective, Multicenter, Single-Arm Clinical Trial for Treatment of Complex Diabetic Foot Ulcers with Deep Exposure Using Acellular Dermal Matrix. Adv Skin Wound Care. 2019 Sep;32(9):409-415. doi: 10.1097/01.ASW.0000569132.38449.c0. PMID: 31361269; PMCID: PMC7328871.
11. LifeNet Health, TR ED-23-0306, In vivo Assessment of Local Tissue Response and Cell Infiltration – Animal study results may not be predictive of clinical results.
12. LifeNet Health, PQ 10-006, Process Qualification: Devitalization of Dermal Allografts

For media inquiries, please contact:
Doug Wilson
[email protected]
757-609-4468, office

SOURCE LifeNet Health